Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.
Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the location details.SummaryDifference5%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedSeveral key resources and links related to genetics and clinical trials have been removed, including important URLs from MedlinePlus and DailyMed, which may impact access to information on lung cancer and specific treatments.SummaryDifference7%
- Check43 days agoChange DetectedThe website has been updated to version 2.12.2, adding several new links related to genetics, clinical trials, and treatment options, while removing the previous version 2.12.1.SummaryDifference8%
- Check50 days agoChange DetectedThe website has been updated from version v2.12.0 to v2.12.1.SummaryDifference0.1%
- Check57 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential enhancements or features.SummaryDifference0.3%
Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.